Your browser is no longer supported. Please, upgrade your browser.
MRK Merck & Co., Inc. daily Stock Chart
Merck & Co., Inc.
IndexDJIA S&P500 P/E33.10 EPS (ttm)1.82 Insider Own0.05% Shs Outstand2.70B Perf Week2.73%
Market Cap162.65B Forward P/E13.51 EPS next Y4.46 Insider Trans-12.75% Shs Float2.69B Perf Month11.33%
Income5.00B PEG5.35 EPS next Q1.00 Inst Own76.40% Short Float0.88% Perf Quarter-1.63%
Sales40.12B P/S4.05 EPS this Y29.20% Inst Trans0.08% Short Ratio1.87 Perf Half Y-5.49%
Book/sh12.65 P/B4.76 EPS next Y6.39% ROA2.60% Target Price66.55 Perf Year-2.65%
Cash/sh3.15 P/C19.14 EPS next 5Y6.19% ROE6.30% 52W Range52.83 - 66.41 Perf YTD7.07%
Dividend1.92 P/FCF- EPS past 5Y-1.90% ROI8.70% 52W High-9.28% Beta0.80
Dividend %3.19% Quick Ratio1.10 Sales past 5Y-3.20% Gross Margin68.80% 52W Low14.05% ATR1.24
Employees69000 Current Ratio1.30 Sales Q/Q3.10% Oper. Margin16.30% RSI (14)71.22 Volatility1.61% 2.21%
OptionableYes Debt/Eq0.71 EPS Q/Q365.20% Profit Margin6.00% Rel Volume1.55 Prev Close58.83
ShortableYes LT Debt/Eq0.62 EarningsMay 01 BMO Payout215.80% Avg Volume12.63M Price60.25
Recom2.00 SMA207.82% SMA508.98% SMA2001.82% Volume19,544,346 Change2.41%
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-18-17Upgrade Citigroup Neutral → Buy
Aug-09-17Upgrade HSBC Securities Reduce → Hold
Jul-31-17Reiterated UBS Buy $70 → $72
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Jan-12-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-12-17Upgrade Guggenheim Neutral → Buy
Apr-23-18 04:30PM  European Medicines Agency Validates Type II Variation for Mercks KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy as First-Line Therapy in Metastatic Nonsquamous NSCLC, Based on Phase 3 KEYNOTE-189 Trial Business Wire
02:04PM  Merck's stock surges to lead Dow's gainers after Goldman turns bullish MarketWatch
10:34AM  Keytruda Is Key To The Merck Thesis, Goldman Sachs Says In Upgrade Benzinga
10:32AM  P&G to buy German Merck's consumer health unit for $4.2 billion Reuters
Apr-20-18 01:51PM  U.S. biotech companies Alnylam, Dicerna settle trade secrets case Reuters
01:05PM  Germany's Merck seeks partners for cancer and immune system drugs Reuters
11:56AM  What's in the Cards for Glaxo (GSK) This Earnings Season? Zacks
10:43AM  Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR Zacks
10:11AM  J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit? Zacks
07:00AM  Fate of Pfizer Unit in Spotlight After Merck Sells Consumer Business
Apr-19-18 08:01PM  Corrections & Amplifications The Wall Street Journal
05:50PM  P&G to buy German Merck's consumer health unit for $4.2 billion Reuters
05:44PM  Bristol-Myers' Opdivo Gets Priority Review for Lung Cancer Zacks
05:40PM  P&G to buy German Merck's consumer health unit for $4.2 billion Reuters
02:51PM  P&G Exec: The Entire Board Was Supportive of Our $4.2 Billion Deal
12:42PM  [$$] P&G Needs a Workout, Not Vitamins The Wall Street Journal
11:31AM  Unilever Plans $7.4 Billion Buyback Bloomberg Video
08:15AM  Procter & Gamble pays $4.2 bln for unit of Germany's Merck Associated Press
07:14AM  P&G Vows More Change Coming After $4.2 Billion Acquisition Bloomberg
Apr-18-18 11:50PM  P&G to Buy German Mercks Consumer Unit for $4.2 Billion Bloomberg
01:09PM  Benzinga's Top Analyst Calls From April 18, 2018 Benzinga
07:45AM  The Newest, Undiscovered CAR-T Play with a Rock-Star Partner Portfolio & Significant Near-Term Upside Potential ACCESSWIRE
Apr-17-18 02:29PM  Coke Versus Pepsi of Drugmakers? Wall Street Doesn't Buy It Bloomberg
02:16PM  One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings Benzinga
11:13AM  Merck's Keytruda Betters Survival in Lung Cancer Combo Study Zacks
10:52AM  Bristol-Myers (BMY) Down as Merck NSCLC Study Fares Better Zacks
09:40AM  J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance Zacks
08:45AM  Company News For Apr 17, 2018 Zacks
08:30AM  Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine Business Wire
08:20AM  Todays Research Reports on Stocks to Watch: Nektar Therapeutics and Merck & Co. ACCESSWIRE
06:58AM  Merck shares surge anew on lung cancer advance, while Bristol-Myers stock plummets MarketWatch
12:45AM  [$$] New Drug Combinations Improve Survival in Lung Cancer The Wall Street Journal
Apr-16-18 04:50PM  Dow Hits Resistance At 50-Day As Apple Stock Moves Higher Investor's Business Daily
02:12PM  The Worst Stock Market Plunge in Your Lifetime Is Coming: Jim Rogers
02:09PM  Merck extends lead over Bristol-Myers in lung cancer race CNBC Videos
01:33PM  Merck Expands Lead Over Bristol-Meyers in Lung Cancer Drugs Bloomberg Video
01:33PM  Merck Expands Lead Over Bristol-Meyers in Lung Cancer Drugs Bloomberg
01:21PM  Merck Tightens Its Grip on the Lung-Cancer Market Bloomberg
01:18PM  Merck to move scientists and money toward promising cancer drug American City Business Journals
12:05PM  [$$] Bristol-Myers Has Farther to Fall The Wall Street Journal
11:35AM  Survival data boosts Merck's Keytruda lead in lung cancer Reuters
11:22AM  Was Merck & Co Inc.s (NYSE:MRK) Earnings Decline Part Of A Broader Industry Downturn? Simply Wall St.
11:17AM  Merck Notches Key Win Over Bristol-Myers on Lung Cancer Study Data
10:18AM  Merck leads Dow industrials higher MarketWatch
10:12AM  Merck shares rise after beating rivals' lung cancer results MarketWatch
09:46AM  Merck, Bristol-Myers immunotherapies impress in key lung cancer trials Reuters
09:38AM  Bristol-Myers and Merck meet cancer study goals CNBC Videos
09:30AM  [$$] New Drug Combinations Improve Survival in Lung Cancer The Wall Street Journal
09:30AM  Mercks KEYTRUDA® (pembrolizumab) Plus Pemetrexed (ALIMTA®) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study Business Wire
09:30AM  Merck Cements Lead in Lung Cancer With Bristol-Myers Fizzling Bloomberg
09:24AM  Bristol-Myers says cancer drug combo reduces death risk Reuters
09:19AM  Bristol-Myers Says Lung Cancer Drug Combination Met Trial Goal Bloomberg
08:30AM  Todays Research Reports on Trending Tickers: Aphria and Merck & Company ACCESSWIRE
Apr-15-18 11:40PM  [$$] Why Merck Is Betting Big on One Cancer Drug The Wall Street Journal
09:30PM  [$$] Merck lung cancer trial boosts immunotherapy hopes Financial Times
04:50PM  Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR Business Wire
09:30AM  Mercks KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percent Compared to Placebo as Adjuvant Therapy in Resected, High-Risk Stage III Melanoma Business Wire
07:00AM  [$$] Why Merck Is Betting Big on One Cancer Drug The Wall Street Journal
Apr-14-18 10:20AM  A shingles vaccine can improve your health especially if youre over 50 MarketWatch
Apr-13-18 02:19PM  Lung cancer battle brews CNBC Videos
01:35PM  Mylan seeks deal for German Merck's consumer products unit - sources Reuters
11:54AM  Merck KGaA Consumer Unit Is a Deal Too Far for Mylan Bloomberg
07:22AM  Drugmakers vie for dominance in lung cancer treatment CNBC Videos
04:50AM  Mylan seeks deal for German Mercks consumer products unit: sources Reuters
Apr-12-18 05:51PM  U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report
10:31AM  Your post-surgery pain could be this San Francisco drugmaker's gain and opioid users may benefit, too American City Business Journals
Apr-10-18 11:09AM  Wall Street Sees Keytruda Cancer Drug Lifting Merck's Fortune
10:15AM  vTv Therapeutics Crashes on Alzheimer's Drug Study Failure Zacks
08:59AM  Merck's Keytruda Offers Survival Benefit in Lung Cancer Study Zacks
Apr-09-18 05:24PM  NewLink Shares Plunge After Incyte & Merck's Study Fails Zacks +5.25%
04:58PM  US STOCKS-Wall St rises but pares gains late after report of FBI raid Reuters
04:39PM  Top Analyst Reports for Microsoft, Merck & Union Pacific Zacks
04:32PM  Why Alcoa, Merck, and Agios Pharmaceuticals Jumped Today Motley Fool
04:15PM  Stocks Pare Gains As Apple Tests Support Again; Bitcoin Drops Investor's Business Daily
03:20PM  US STOCKS-Wall St indexes rise over 1 pct as trade worries ease Reuters
11:25AM  This Lung Cancer Drug Could Let Patients Forgo ChemoAnd Its Sending Mercks Stock Soaring Fortune
10:33AM  Merck's Keytruda helps lung cancer patients live longer in trial Reuters
09:48AM  Merck's Keytruda meets main goal in pivotal lung cancer trial Reuters
09:48AM  Incyte's Epacadostat Fails in Melanoma Study, Shares Plunge Zacks
09:30AM  Stocks to Watch: Leucadia, Caterpillar, Boeing, Merck, PayPal The Wall Street Journal
08:10AM  Todays Research Reports on Stocks to Watch: Incyte and Merck ACCESSWIRE
07:39AM  US STOCKS-Futures higher as U.S.-China trade war fears ease Reuters
07:00AM  Merck's stock surges after positive Keytruda trial results MarketWatch
06:45AM  KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor Cells Business Wire
05:05AM  South Africa may ask pharma firms for fee to clear drug review backlog Reuters
Apr-06-18 10:57PM  [$$] Incyte Shares Tumble After Cancer Drug Fails in Trial With Mercks Keytruda The Wall Street Journal
12:41PM  [$$] Incyte Shares Fall After Cancer Drug Fails in Trial With Merck's Keytruda The Wall Street Journal
12:19PM  Incyte Corporation Stock Plunges on Melanoma Drug Trial Failure InvestorPlace
11:19AM  Incyte stock plummets following disappointing clinical study results American City Business Journals
10:11AM  Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus Zacks
09:30AM  Stocks to Watch: Incyte, JPMorgan, Boeing, WageWorks The Wall Street Journal
08:04AM  Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment MarketWatch
07:44AM  Incyte's combo therapy for skin cancer fails in late-stage study Reuters
07:30AM  Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma Business Wire
06:00AM  Cancer killer: Tampas best-kept secret M2Gen collects data from labs and bedsides to help target treatments American City Business Journals
Apr-05-18 07:40AM  Wired News Merck and AstraZeneca Announced that EMA Will Review MAA for LYNPARZA(R) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer ACCESSWIRE
Apr-03-18 06:00AM  The European Medicines Agency Accepts Regulatory Submission for LYNPARZA® (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer Business Wire
Apr-02-18 06:45AM  Merck to Hold First-Quarter 2018 Sales and Earnings Conference Call on May 1 Business Wire
Mar-30-18 10:40AM  Walmart may make a major splash in the health care industry Yahoo Finance Video
Mar-28-18 01:56PM  What Knocked ImmunoGen, Inc. Down 15% on Tuesday? Motley Fool
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., and IO Biotech. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GRADDICK WEIR MIRIAN MExe V-P, HRApr 16Sale58.0024,0001,392,00080,433Apr 17 05:56 PM
WEEKS WENDELL PDirectorFeb 09Option Exercise38.045,000190,2005,100Feb 09 04:48 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthFeb 09Option Exercise0.008,572045,780Feb 09 04:48 PM
WEEKS WENDELL PDirectorFeb 09Sale53.575,000267,833100Feb 09 04:48 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Option Exercise36.5650,9941,864,34150,994Jan 16 05:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Option Exercise44.3052,0002,303,600153,484Jan 16 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Sale61.6360,0003,697,80093,484Jan 16 05:12 PM
Holston Michael JEVP, General CounselJan 16Sale61.6312,500770,37549,092Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,6083,118,97162,766Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,9943,142,7600Jan 16 05:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 12Sale58.005,000290,000101,484Jan 16 05:12 PM
GLOCER THOMAS HDirectorNov 08Option Exercise38.045,000190,20010,100Nov 09 03:52 PM
GLOCER THOMAS HDirectorNov 08Sale56.205,000280,9835,100Nov 09 03:52 PM
KIDDER C ROBERTDirectorMay 12Option Exercise35.195,000175,95014,317May 12 04:58 PM
KIDDER C ROBERTDirectorMay 12Sale63.545,000317,6959,317May 12 04:58 PM
Davis Robert MEVP, Global Svcs & CFOMay 09Option Exercise0.0085,8810118,031May 09 04:42 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 09Option Exercise0.002,576023,668May 09 04:42 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 09Option Exercise0.002,576017,068May 09 04:42 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 02Option Exercise0.003,092043,637May 03 09:54 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 02Option Exercise0.003,092046,416May 03 09:52 AM